You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Refanalin for lung preservation and transplantation

    SBC: Angion Biomedica Corp.            Topic: N/A

    DESCRIPTION (provided by applicant): Lung transplantation is the only effective treatment modality for patients with end-stage lung disease. Ischemia-reperfusion injury, associated with the retrieval, storage and transplantation of the lung is a major immu ne-independent factor adversely affecting early graft function, graft viability and recipient morbidity and mortality. Marginal donor lungs, ar ...

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  2. ECIS-based High Throughput Screening Instrumentation

    SBC: APPLIED BIOPHYSICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The long-term objective of the research is to develop and fabricate an instrument that can facilitate the discovery of new drugs via high throughput screening (HTS). ECIS (electric cell-substrate impedance sensing) is a technology developed by Applied BioPhysics to study the behavior of cultured cells in real time. Instruments manufactured by the company curre ...

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  3. The DBT-SUD In-Session Response to Dysfunctional Behavior for ACT Teams

    SBC: BEHAVIORAL TECH RESEARCH, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Persons with severe and persistent mental illness (SPMI) commonly experience both Substance Use Disorders (SUDs) and Borderline Personality Disorder (BPD), resulting in serious and complex personal costs and public heal th problems. Although Assertive Community Treatment (ACT) is efficacious for persons with SPMI, it is less clear the extent to which this appro ...

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  4. Computer-Based Training in Panic Control Treatment for Adolescents

    SBC: BEHAVIORAL TECH RESEARCH, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): This is a Phase II Small Business Innovation Research (SBIR; R43/44) grant application to NIMH to support the further development and testing of an innovative, online training program in Panic Control Treatment for Adol escents (PCT-A). The current application represents a cooperative partnership between the PI's small business concern, Behavioral Tech Research ...

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  5. Hypothermic Storage and Cryopreservation of Corneas

    SBC: CELL PRESERVATION SERVICES INC            Topic: N/A

    DESCRIPTION (provided by applicant): Cell Preservation Services, Inc. (CPSI) is a biotechnology company dedicated to the development of novel technologies in the area of low temperature biology and medicine. CPSI's core molecular strategy is focused on und erstanding and manipulating the cell survival and cell death pathways that appear to be cell-specific and are activated as a consequence of low ...

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  6. Proof-of-Concept for Card-based CD4 Cell Counting

    SBC: E.I. SPECTRA, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): The long-term objective of this proposed research is to develop a simple, inexpensive point-of-care device that will perform absolute and percent CD4+ T cell counts from whole blood. This will be accomplished by adaptin g and testing a novel hybrid approach to microfluidic sample preparation and analysis. One-time use thin-film laminated microfluidic cassette ...

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  7. System for generation of frozen-hydrated samples using the Focused Ion Beam

    SBC: Hummingbird Precision Machine Co.            Topic: N/A

    Project Summary The long term objective of our application is to develop hardware and procedures that will allow researchers to better understand the function of the cell. Our specific aim is to provide a system that will allow researches to better prepare frozen hydrated specimens for study via tomographic reconstruction in the transmission electron microscope(TEM) Current methods of preparing f ...

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  8. Dock and Lock: Novel Protein Engineering

    SBC: IMMUNOMEDICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The objective of this Phase II application is the commercial development of CEA-ImmunoPET for breast cancer imaging. CEA-ImmunoPET is a two-component product system comprising TF2, a trivalent, bispecific, anti-CEA x an ti-HSG constructs made by the Dock and Lock (DNL) method, and 68Ga-IMP288, a DOTA- derivatized di-HSG peptide radiolabeled with 68Ga. In the Ph ...

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  9. MAb-based targeted chemotherapy of lung cancer

    SBC: IMMUNOMEDICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Lung cancer is one of the most common malignancies worldwide, and the 5-year survival rate is only 15%. As existing therapies do not significantly increase survival rate, there is an urgent need to develop newer therapi es that can augment the existing treatments. The goal of the proposed work is to produce a safe and effective targeted chemotherapy for the tre ...

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  10. An anti-CD74 MAb-drug conjugate for B-cell malignancies

    SBC: IMMUNOMEDICS, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): The goal of this work is to develop an antibody-doxorubicin conjugate for the targeted therapy of B-cell cancers that express the CD74 antigen. The Phase II project will focus on advancing this product for multiple myel oma, a common plasma cell malignancy that is incurable at this time. The average 5-year survival rate for these patients is only 30%, and there ...

    SBIR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government